#USA #San Diego #Class Action #Robbins LLP #Picard Medical

Class Action Lawsuit Against Picard Medical, Inc.

The investment community is closely watching developments concerning Picard Medical, Inc. (NYSE: PMI), following the announcement by Robbins LLP that a class action lawsuit has been filed on behalf of shareholders. This legal action pertains to all investors who acquired PMI stocks between September 2 and October 31, 2025. The firm highlights the importance of this case for investors who may have suffered significant losses due to alleged fraudulent activities linked to the company's stock trading.

Allegations Against Picard Medical

Robbins LLP has identified multiple serious allegations against Picard Medical. The company is accused of being involved in a problematic stock promotion scheme driven by misinformation circulated on social media channels. Investors are reportedly misled by fake financial advisors and manipulated narratives that inflated the company's stock price artificially.

The complaint specifies that insiders engaged in deceitful actions, utilizing offshore accounts to sell stocks at inflated prices, confirming the concerns around market integrity and transparency within the company. Additionally, key public statements made by Picard Medical failed to disclose critical information about these manipulative activities, which could have influenced investor decisions.

On October 24, 2025, the negative implications of these alleged practices became apparent when Picard Medical's stock suffered a catastrophic drop of 70%, plummeting from its previous price to just $3.99 per share. Since that time, the stock has continued to falter, with recent trading revealing prices around $2.00 per share. This dramatic decline has prompted concerned investors to seek justice through this class action suit.

Next Steps for Investors

Investors who purchased shares during the specified time frame may be eligible to participate in this class action lawsuit. Those interested in becoming lead plaintiffs must submit their applications to the court by April 3, 2026. Serving as a lead plaintiff gives an investor a unique role in guiding the litigation process, representing the interests of all class members. However, there is no requirement for class members to actively participate to be entitled to potential recoveries related to the lawsuit.

Robbins LLP emphasizes that their representation is contingent fee-based, meaning shareholders incur no initial costs. This funding structure is designed to support investors in pursuing claims without financial burdens upfront.

About Robbins LLP

With a proven track record in advocating for shareholder rights since 2002, Robbins LLP has established itself as a leader in the field of securities litigation. The firm is dedicated to helping investors recover losses, ensuring corporate accountability, and advocating for stronger corporate governance reforms. Robbins LLP's commitment to advancing shareholder interests is a crucial part of their mission.

For those wishing to stay updated on the progress of this lawsuit or to receive notifications concerning other instances of corporate misconduct, Robbins LLP recommends signing up for their Stock Watch alerts. This resource provides essential information about significant developments in the realm of corporate governance and investor rights.

Conclusion

Investors who feel they may have been impacted by Picard Medical's alleged fraudulent practices are encouraged to reach out to Robbins LLP for further guidance and assistance. The goal of this class action is not only to provide compensation for losses incurred but also to foster corporate accountability and improve investor protections going forward. It highlights the ongoing challenges in maintaining market integrity and the need for vigilance among investors navigating potential risks.